recormon pre-filled syringe 10000 iu0.6 ml
roche singapore pte. ltd. - epoetin beta - injection - 10000 iu/0.6 ml - epoetin beta 10000 iu/0.6 ml
recormon pre-filled syringe 2000 iu0.3 ml
roche singapore pte. ltd. - epoetin beta - injection - 2000 iu/0.3 ml - epoetin beta 2000 iu/0.3 ml
recormon solution for i/v and s/c injection
roche diagnostics gmbh - epoetin beta - solution for i/v and s/c injection - 2000iu/0,3ml
recormon pre-filled syringe 4000 iu0.3 ml
roche (malaysia) sdn. bhd. - epoetin beta -
recormon pre-filled syringe 2000iu0.3ml
roche (malaysia) sdn. bhd. - epoetin beta -
recormon pre-filled syringe 5000iu0.3ml
roche (malaysia) sdn. bhd. - epoetin beta -
recormon pre-filled syringes 2000iu/0.3ml
roche (malaysia) sdn. bhd. - epoetin beta -
recormon pre-filled syringes 4000iu/0.3ml
roche (malaysia) sdn. bhd. - epoetin beta -
aranesp darbepoetin alpha (rch) 60 microgram/0.3ml injection syringe with automatic needle guard
amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; sodium chloride; monobasic sodium phosphate monohydrate; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy
aranesp darbepoetin alfa (rch) 80 microgram/0.4ml injection syringe with automatic needle guard
amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; polysorbate 80; sodium chloride; dibasic sodium phosphate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy